Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs)

Toxicology and Applied Pharmacology

Volumn 267, Issue 2, 2013, Pages 149-154

  Fang, Zhong Ze ^a,c,d   Cao, Yun Feng ^b,c   Hu, Cui Min ^d   Hong, Mo ^c   Sun, Xiao Yu ^c   Ge, Guang Bo ^c   Liu, Yong ^c   Zhang, Yan Yan ^c   Yang, Ling ^c   Sun, Hong Zhi ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^c DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ginseng drug interaction; Ginsenosides; UDP glucuronosyltransferases (UGTs)

Indexed keywords

GINSENOSIDE RG 3; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B7; HYMECROMONE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; ENZYME INHIBITION; GLUCURONIDATION; HERB DRUG INTERACTION; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION;

GINSENOSIDES; GLUCURONOSYLTRANSFERASE; HERB-DRUG INTERACTIONS; HUMANS; HYMECROMONE; ISOENZYMES; PANAX; STRUCTURE-ACTIVITY RELATIONSHIP;

PANAX GINSENG;

EID: 84872863938     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.12.019     Document Type: Article

References (26)

1. Attele A.S., et al. Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol. 1999, 58:1685-1693.
2. Dong R.H., et al. Investigation of UDP-glucuronosyltransferases (UGT) inhibitory properties of carvacrol. Phytother. Res. 2012, 26(1):86-90.
3. Fang Z.Z., et al. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br. J. Clin. Pharmacol. 2010, 69(2):193-199.
4. Fang Z.Z., et al. Identification of cytochrome P450 (CYP) isoforms involved in metabolism of corynoline and assessment of its herb-drug interaction. Phytother. Res. 2011, 25:256-263.
5. Fang Z.Z., et al. Bioactivation of herbal constituents: simple alerts in the complex system. Expert Opin. Drug Metab. Toxicol. 2011, 7(8):989-1007.
6. Huang T., et al. Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDP-Glucuronosyltransferase (UGT) 2B7 might induce drug-drug interactions (DDIs). Pharmazie 2010, 65(12):919-921.
7. Huang T., et al. Inhibitory potential of chlormadinone acetate (CMA) on five important UDP-glucurosyltransferases in human liver. Pharmazie 2011, 66:212-215.
8. Janetzky K., Morreale A.P. Probable interaction between warfarin and ginseng. Am. J. Health Syst. Pharm. 1997, 54:692-693.
9. Kiang T.K., et al. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 2005, 106:97-132.
10. King C.D., et al. UDP-glucuronosyltransferases. Curr. Drug Metab. 2000, 1:143-161.
11. Liu Y., et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol. Sci. 2006, 91(2):356-364.
12. Mackenzie P.I., et al. Nomenclature update for the mammalian UDP-glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics 2005, 15:677-685.
13. Meza-Junco J., et al. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother. Pharmacol. 2009, 65(1):1-4.
14. Miller G.P., et al. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem. Res. Toxicol. 2009, 22(7):1239-1245.
15. Nakamura A., et al. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab. Dispos. 2008, 36:1461-1464.
16. Qi L.W., et al. American ginseng: potential structure-function relationship in cancer chemoprevention. Biochem. Pharmacol. 2010, 80(7):947-954.
17. Qi L.W., et al. Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry 2011, 72:689-699.
18. Qi L.W., et al. Metabolism of ginseng and its interactions with drugs. Curr. Drug Metab. 2011, 12(9):818-822.
19. Raungrut P., et al. In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J. Pharmacol. Exp. Ther. 2010, 334(2):609-618.
20. Shader R.J., Greenblatt D.J. Phenelzine and the dream machine-ramblings and reflections. J. Clin. Psychopharmacol. 1985, 5(2):65.
21. Uchaipichat V., et al. Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. Drug Metab. Dispos. 2011, 39(8):1324-1328.
22. Yao Y., et al. The inhibition effect of 20(S)-protopanaxadiol (PPD) and ginsenoside Rh2 for CYP2C9 and CYP3A4. Polymer 2007, 48:2644-2648.
23. Zhao Q., et al. Determination of ginsenoside Rg3 in human plasma and urine by high performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2010, 878(24):2266-2273.
24. Zhu L.L., et al. Potent and selective inhibition of magnolol on catalytic activities of UGT1A7 and 1A9. Xenobiotica 2012, 42(10):1001-1008.
25. Zielinska A., et al. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. J. Pharmacol. Exp. Ther. 2008, 324:139-148.
26. Zucker S.D., et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl. Acad. Sci. U. S. A. 2001, 99(22):12671-12676.